 |
|
|
| |
TURQUOISE-I Part 2: safety and efficacy of ombitasvir + paritaprevir/r ± dasabuvir with or without RBV in patients with HIV-1 and HCV GT1 or GT4 co-infection
|
| |
| |
Reported by Jules Levin
Durban 2016 July 18-22
J.K. Rockstroh1, C. Orkin2, R.M. Viani3, D. Wyles4, A. Luetkemeyer5, A. Lazzarin6, R. Soto-Malave7, M. Nelson8, S.R. Bhagani9, H.H.F. Klinker10, G. Rizzardini11, P.-M. Girard12, N.S. Shulman3, Y.B. Hu3, L.M. Fredrick3, R. Trinh3, E. Gane13
Institutions
1Universitätsklinikum Bonn, Bonn, Germany, 2The Royal London Hospital, London, United Kingdom, 3AbbVie, Inc., North Chicago, United States, 4University of California San Diego, La Jolla, United States, 5San Francisco General Hospital, San Francisco, United States, 6Fondazione Centro San Raffaele del Monte Tabor, Milan, Italy, 7Innovative Care P.S.C., Bayamon, Puerto Rico, 8Chelsea and Westminster Hospital, London, United Kingdom, 9Royal Free London Foundation Trust, London, United Kingdom, 10Universitätsklinikum Wuerzburg, Wuerzberg, Germany, 11ASST Fatebenefratelli Sacco, Milan, Italy, 12Hopital Saint Antoine, Paris, France, 13Liver Unit, Auckland City Hospital, Auckland, New Zealand
|
| |
|
|
|
|
|
